Exscientia plc (NASDAQ:EXAI) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its stake in Exscientia plc (NASDAQ:EXAI) by 108.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 388,459 shares of the company’s stock after purchasing an additional 202,377 shares during the period. Bank of New York Mellon Corp owned about 0.32% of Exscientia worth $1,981,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Private Advisor Group LLC increased its stake in shares of Exscientia by 114.3% in the 4th quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock valued at $144,000 after purchasing an additional 12,000 shares in the last quarter. Jump Financial LLC increased its position in shares of Exscientia by 47.7% in the fourth quarter. Jump Financial LLC now owns 53,755 shares of the company’s stock valued at $345,000 after buying an additional 17,355 shares in the last quarter. New Republic Capital LLC acquired a new position in shares of Exscientia during the 4th quarter worth approximately $128,000. Walled Lake Planning & Wealth Management LLC acquired a new position in shares of Exscientia during the 4th quarter worth approximately $64,000. Finally, GAMMA Investing LLC lifted its position in shares of Exscientia by 112.1% during the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after buying an additional 2,302 shares in the last quarter. Institutional investors and hedge funds own 41.58% of the company’s stock.

Exscientia Price Performance

EXAI stock opened at $5.03 on Wednesday. Exscientia plc has a 52-week low of $3.80 and a 52-week high of $7.91. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.06. The stock has a market cap of $608.06 million, a price-to-earnings ratio of -3.87 and a beta of 0.86. The business has a fifty day moving average of $5.25 and a two-hundred day moving average of $5.23.

Exscientia (NASDAQ:EXAI) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). The business had revenue of $5.60 million for the quarter. Exscientia had a negative return on equity of 37.56% and a negative net margin of 620.99%. As a group, research analysts anticipate that Exscientia plc will post -1.25 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on EXAI. TD Cowen reiterated a “hold” rating on shares of Exscientia in a report on Friday, August 9th. Barclays reaffirmed an “equal weight” rating and issued a $5.00 price target on shares of Exscientia in a research note on Tuesday, August 13th.

Exscientia Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.